Annual report pursuant to Section 13 and 15(d)

Collaborative Arrangements - Molecular Associates Inc (Details)

v3.20.4
Collaborative Arrangements - Molecular Associates Inc (Details) - USD ($)
1 Months Ended 12 Months Ended
Jun. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Investment in non-marketable securities   $ 2,000,000 $ 0 $ 0
Contract liabilities, deferred revenue   4,791,000 2,044,000  
Contract assets   4,526,000 $ 1,027,000  
Molecular Assemblies, Inc.        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Contract assets   500,000    
Molecular Assemblies, Inc. | Master Collaboration & Research Agreement        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Revenue recognized from transactions   $ 900,000    
Molecular Assemblies, Inc. | Master Collaboration & Research Agreement | Bonus Goal Met        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Number of days for payment 30 days      
Molecular Assemblies, Inc. | Commercialization And Enzyme Supply Agreement        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Aggregate commercial sales, milestone $ 5,000,000.0      
Molecular Assemblies, Inc. | Commercialization And Enzyme Supply Agreement | Revenue sharing arrangement        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Contract liabilities, deferred revenue $ 500,000      
Series A Preferred Stock | Molecular Assemblies, Inc. | Master Collaboration & Research Agreement        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Investment owned, balance (in shares)   714,171    
Molecular Assemblies, Inc. | Series A Preferred Stock        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Investment owned, balance (in shares) 1,587,050      
Investment in non-marketable securities $ 1,000,000.0